Canexis obtains Swissmedic approval for cannabis products
Schlattingen - Canexis Pharma has obtained approval from medical supervisory authority Swissmedic to manufacture medical cannabis products. This means the company is authorized to produce high-quality CBD and THC-based drugs for the domestic and international market.
Canexis, a pharmaceutical company based in Schlattingen in the canton of Thurgau, has obtained approval from the Swiss authorization and supervisory authority for medical products to produce cannabis-based medicines. According to a press release, the issued licenses give the company permission to produce CBD and THC-based active pharmaceutical ingredients for the national and international market. The current licensing round was preceded by a four-year preparatory phase, during which a 2,000-square meter production facility was built and equipped with state-of-the-art technology in cleanrooms. Production has now begun, and Canexis will start to supply drugs to pharmacies, hospitals and other pharmaceutical companies later this year.
“In just four years, our team built a pharmaceutical company from the ground up, despite several global challenges,” says Sebastian Zeller, CEO of Canexis. “We are pleased to now be able to take a new perspective from the focus of the development and to make an active contribution to the development of the cannabis medicine market.” ce/eb
